228M-1

BG8, Lewis^Y (F3) Mouse Monoclonal Antibody

• NACRES: NA.41
• UNSPSC Code: 12352203
• Conjugate: unconjugated
• Clone: F3, monoclonal
• Application: IHC (p)
• Citations: 5

Propiedades

• biological source: mouse
• Quality Segment: 100, 500
• conjugate: unconjugated
• antibody form: culture supernatant
• antibody product type: primary antibodies
• clone: F3, monoclonal
• description: For In Vitro Diagnostic Use in Select Regions (See Chart)
• form: buffered aqueous solution
• species reactivity: human
• packaging: vial of 0.1 mL concentrate (228M-14), vial of 0.5 mL concentrate (228M-15), bottle of 1.0 mL predilute (228M-17), vial of 1.0 mL concentrate (228M-16), bottle of 7.0 mL predilute (228M-18)
• manufacturer/tradename: Cell Marque^®
• technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:10-1:50
• isotype: IgM
• control: adenocarcinoma of lung
• shipped in: wet ice
• storage temp.: 2-8°C
• visualization: cytoplasmic
• Gene Information: human ... F3(2152)

Descripción

General description

Blood group antigens have been examined as potential discriminators between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). Lewis^y is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and its ability to distinguish between PACA and EM was first reported by Jordon and colleagues in 1989. Three groups have since reported their results. These studies included 231 cases of PACA and 197 cases of EM. Sensitivity and specificity for PACA were both 93%. Yaziji H et al. reported a sensitivity of nonmesothelial antigens for adenocarcinoma as organ dependent, with BG8 performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8. They concluded using logical regression analysis that a three-antibody immunohistochemical panel including calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from adenocarcinoma from a variety of sources (lung, ovary, breast, stomach).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Analysis Note

IVD

IVD

IVD

RUO

Other Notes

BG8 Positive Control Slides, Product No. 228S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

For Technical Service please contact: 800-665-7284 or email: [email protected]

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany